Urinary enzyme measurements as early indicators of renal insult in type 2 diabetes

References

• Panchapakesan U, Xin-Ming C, and Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy – relevance to renoprotection. Nat Clin Pract Nephrol 2005; 1: 33–43.
   Google Scholar
• Mogenson CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. Diabetes 1993; 32: 64S–78S.
   Google Scholar
• Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent diabetic patients. N Engl J Med 1984; 311: 89–93.
   Google Scholar
• Friedman EA, Friedman AL. Is there really good news about pandemic diabetic nephropathy? Nephrol Dial Transplant 2007; 22: 681–3.
   Google Scholar
• Perrone RD, Madias NE, Levy AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933–53.
   Google Scholar
• Turner RC. The UK Prospective Diabetes Study: a review. Diabetes Care 1998; 15 (Suppl 4): S47–S50.
   Google Scholar
• Whiting PH, Price RG. Importance of early detection of renal dysfunction: value of markers of early renal disease and damage. Clin Biochem 2001; 3: 3–8.
   Google Scholar
• Jung K, Pergande M, Schimke E, Ratzman KP, Illus A. Urinary enzymes and low molecular mass protein as indicators of diabetic nephropathy. Clin Chem 1988; 34: 544–77.
   Google Scholar
• Uslu S, Efe B, Alatas O et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol 2005; 18: 559–67.
   Google Scholar
• Price RG, Whiting PH. Urinary enzymes and nephrotoxicity in humans. In: Jung K, Matternheimer H, Burchards U eds. Urinary enzymes. Heidelberg: Springer-Verlag, 1992: 203–21.
   Google Scholar
• Whiting PH, Ross IS, Borthwick L. Serum and urine N-acetyl-β-D-glucosaminidase in diabetics on diagnosis and subsequent treatment, and stable insulin-dependent diabetics. Clin Chim Acta 1979; 92: 459–63.
   Google Scholar
• Watts GF, Vltos MA, Morris RW, Price RG. Urinary N-acetyl-beta-D-glucosaminidase excretion in insulin-dependent diabetes mellitus: relation to microalbuminuria, retinopathy and glycaemic control. Diabetes Metab 1988; 14: 653–8.
   Google Scholar
• Nakamura S. Clinical evaluation of urinary alanine aminopeptidase in the patients with diabetes mellitus – comparison among AAP, microalbumin and N-acetyl-β-D-glucosaminidase (Japanese). Hokkaido Igaku Zasshi 1991; 66: 522–33.
   Google Scholar
• Jones AP, Lock S, Griffiths KD. Urinary N-acetyl-betaglucosaminidase activity in type 1 diabetes mellitus. Ann Clin Biochem 1995; 32: 58–62.
   Google Scholar
• Koh KTC, Chia KS, Tan C. Proteinuria and enzymuria in noninsulin-dependent diabetics. Diabetes Res Clin Pract 1993; 20: 215–21.
   Google Scholar
• Hong C-Y, Hughes K, Chia K-S, Ng V, Ling S-L. Urinary α1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care 2003; 26: 338–42.
   Google Scholar
• Aksun SA, Özmen, Özmen B et al. β2-microglobulin and cystatin C in type 2 diabetes: assessment of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2004; 112: 195–200.
   Google Scholar
• Whiting PH, Ross IS, Borthwick. N-acetyl-β-D-glucosaminidase levels and the onset of diabetic microangiopathy. Ann Clin Biochem 1983; 20: 15–9.
   Google Scholar
• Branten AJ, Mulder TP, Peters WH, Assmann KJ, Wetzels JF. Urinary excretion of glutathione S transferase alpha and pi in patients with proteinuria: reflection of the site of tubular injury. Nephron 2000; 85: 120–6.
   Google Scholar
• Harrison DJ, Kharbanda R, Cunningham DS, McLellan, Hayes LI. Distribution of glutathione S-transferase isoenzymes in human kidney: basis for possible markers of renal injury. J Clin Pathol 1989; 42: 624–8.
   Google Scholar
• Shaw M. The use of histologically defined specific biomarkers in drug development with special reference to the glutathione transferases. Cancer Biomark 2005; 1: 69–74.
   Google Scholar
• Pergande M, Jung K, Precht S, Fels LM, Herbort C, Stolte H. Changed excretion of urinary proteins and enzymes by chronic exposure to lead. Nephrol Dial Transplant 1994; 9: 613–8.
   Google Scholar
• Kurrle-Weittenhiller A, Engel W. Immunoturbidometric determination of urinary α1-microglobulin on Hitachi analysers. Clin Chem 1992; 38: 1090–1.
   Google Scholar
• Sánchez-Hueso MC, Mateo-Caãs J, Zamora-Madaria E. Influence of glycaemic blood glucose control and incipient diabetic nephropathy on the urinary excretion of N-acetylglucosaminidase (NAG) in diabetes mellitus (Spanish). An Med Interna 1995; 12: 216–20.
   Google Scholar
• Watts GF, Vlitos MA, Morris RW, Price RG. Urinary N-acetylbeta-D-glucosaminidase excretion in insulin-dependent diabetes mellitus: relation to microalbuminuria, retinopathy and glycaemic control. Diabetes Metab 1988; 14: 653–8.
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813–20.
   Google Scholar
• Nishikawa T, Eidelskein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int 2000; 71: S26–S30.
   Google Scholar
• Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 2007; 9: 343–53.
   Google Scholar
• Fujita H, Haseyama T, Kayo T et al. Increased expression of glutathione S-transferase in renal proximal tubules in the early stages of diabetes: a study of type-2 diabetes in the Akita mouse model. Exp Nephrol 2001; 9: 380–6.
   Google Scholar
• VanderJagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL. Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. Clin Biochem 2001; 34: 265–70.
   Google Scholar